Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seung T. | - |
dc.contributor.author | Choi, Yoon J. | - |
dc.contributor.author | Park, Kyong H. | - |
dc.contributor.author | Oh, Sang C. | - |
dc.contributor.author | Seo, Jae H. | - |
dc.contributor.author | Shin, Sang W. | - |
dc.contributor.author | Kim, Jun S. | - |
dc.contributor.author | Kim, Yeul H. | - |
dc.date.accessioned | 2021-09-07T14:40:52Z | - |
dc.date.available | 2021-09-07T14:40:52Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2011-03 | - |
dc.identifier.issn | 1743-7555 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/112980 | - |
dc.description.abstract | Aim: There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI). Methods: We analyzed 20 patients between August 2002 and March 2008 with metastatic CRC who had been treated with capecitabine monotherapy after the failure of FOLFOX and FOLFIRI. Results: Overall, one partial response was observed (overall response rate, 5%) and stable disease was observed in 11 patients (55.0%). The disease control rate was 60.0%. The median progression-free survival (PFS) was 2.3 months (95% CI 1.9-2.7) and the median overall survival (OS) was 5.3 months (95% CI 4.6-6.0). Patients without ascites had longer PFS than those with ascites (P = 0.02). Patients with more than three metastatic sites had poorer OS than those with less than two (P = 0.01). Grade 3 or 4 non-hematological toxicities included hand-foot syndrome in one patient. There were no grade 3 or 4 hematological toxicities or treatment-related deaths. Conclusion: The capecitabine monotherapy had a moderate disease control rate and a tolerable toxicity profile as third-line or fourth-line treatment for metastatic CRC patients who were refractory to standard chemotherapy with no further treatment options. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | ORAL FLUOROPYRIMIDINE CARBAMATE | - |
dc.subject | PHASE-II | - |
dc.subject | FLUOROURACIL | - |
dc.subject | LEUCOVORIN | - |
dc.subject | 5-FLUOROURACIL | - |
dc.subject | COMBINATION | - |
dc.subject | CETUXIMAB | - |
dc.subject | TUMORS | - |
dc.subject | TRIAL | - |
dc.subject | PLUS | - |
dc.title | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Seung T. | - |
dc.contributor.affiliatedAuthor | Choi, Yoon J. | - |
dc.contributor.affiliatedAuthor | Park, Kyong H. | - |
dc.contributor.affiliatedAuthor | Oh, Sang C. | - |
dc.contributor.affiliatedAuthor | Seo, Jae H. | - |
dc.contributor.affiliatedAuthor | Shin, Sang W. | - |
dc.contributor.affiliatedAuthor | Kim, Jun S. | - |
dc.contributor.affiliatedAuthor | Kim, Yeul H. | - |
dc.identifier.doi | 10.1111/j.1743-7563.2010.01363.x | - |
dc.identifier.scopusid | 2-s2.0-79951743023 | - |
dc.identifier.wosid | 000287485400013 | - |
dc.identifier.bibliographicCitation | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, v.7, no.1, pp.82 - 87 | - |
dc.relation.isPartOf | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | - |
dc.citation.title | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | - |
dc.citation.volume | 7 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 82 | - |
dc.citation.endPage | 87 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | ORAL FLUOROPYRIMIDINE CARBAMATE | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | LEUCOVORIN | - |
dc.subject.keywordPlus | 5-FLUOROURACIL | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | CETUXIMAB | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | PLUS | - |
dc.subject.keywordAuthor | capecitabine | - |
dc.subject.keywordAuthor | FOLFIRI | - |
dc.subject.keywordAuthor | FOLFOX | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.